Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 12, 2007, Pages 4686-4695

  Liu, Dingxie ^a   Liu, Zhi ^a   Jiang, David ^a   Dackiw, Alan P ^a   Xing, Michael Mingzhao ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYROID CANCER; TUMOR XENOGRAFT; WILD TYPE;

MUS MUSCULUS;

EID: 36849073741     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0097     Document Type: Article

References (46)

1. Leenhardt L, Grosclaude P, Cherie-Challine L 2004 Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 14:1056-1060
2. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167
3. Mazzaferri EL 2007 An overview of the management of thyroid cancer. In: Mazzaferri EL, Harmer C, Mallick UK, Kendall-Taylor P, eds. Practical management of thyroid cancer: a multidisciplinary approach. London: Springer-Verlag; 1-28
4. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK, eds. 2006 SEER cancer statistics review, 1975-2003. Bethesda, MD: National Cancer Institute (http://seer.cancer.gov/csr/1975_2003/. based on November 2005 SEER data submission, posted to the SEER web site, 2006)
5. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648
6. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ 2005 Cancer statistics, 2005. CA Cancer J Clin 55:10-30
7. Torii S, Nakayama K, Yamamoto T, Nishida E 2004 Regulatory mechanisms and function of ERK MAP kinases. J Biochem (Tokyo) 136:557-561
8. MacCorkle RA, Tan TH 2005 Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys 43:451-461
9. Mercer KE, Pritchard CA 2003 Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653:25-40
10. Sebolt-Leopold JS 2004 MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr Pharm Des 10:1907-1914
11. Rodriguez-Viciana P, Tetsu O, Oda K, Okada J, Rauen K, McCormick F 2005 Cancer targets in the Ras pathway. Cold Spring Harb Symp Quant Biol 70:461-467
12. Kohno M, Pouyssegur J 2006 Targeting the ERK signaling pathway in cancer therapy. Ann Med 38:200-211
13. Fagin JA 2005 Genetics of papillary thyroid cancer initiation: implications for therapy. Trans Am Clin Climatol Assoc 116:259-269
14. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262
15. Ciampi R, Nikiforov YE 2005 Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 16:163-172
16. Kondo T, Ezzat S, Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292-306
17. Chiloeches A, Marais R 2006 Is BRAF the Achilles' heel of thyroid cancer? Clin Cancer Res 12:1661-1664
18. Allen LF, Sebolt-Leopold J, Meyer MB 2003 CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 30:105-116
19. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB 2004 Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22:4456-4462
20. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P, Van Becelaere K, Herrera R, Sebolt-Leopold J, Meyer MB 2005 Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23:5281-5293
21. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N 2006 BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-362
22. Welkos S, O'Brien A 1994 Determination of median lethal and infectious doses in animal model systems. Methods Enzymol 235:29-39
23. Gray MJ, Wey JS, Belcheva A, McCarty MF, Trevino JG, Evans DB, Ellis LM, Gallick GE 2005 Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors. Cancer Res 65:3664-3670
24. Katzenstein HM, Rademaker AW, Senger C, Salwen HR, Nguyen NN, Thorner PS, Litsas L, Cohn SL 1999 Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin Cancer Res 5:4273-4278
25. Barbacid M 1987 ras genes. Annu Rev Biochem 56:779-827
26. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA 2002 Mutations of the BRAF gene in human cancer. Nature 417:949-954
27. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE, Fagin JA 2005 Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65:4238-4245
28. Thompson N, Lyons J 2005 Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5:350-356
29. Compton MM 1992 A biochemical hallmark of apoptosis: internucleosomal degradation of the genome. Cancer Metastasis Rev 11:105-119
30. Duriez PJ, Shah GM 1997 Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 75:337-349
31. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J 1996 Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 271:20608-20616
32. Cheng M, Sexl V, Sherr CJ, Roussel MF 1998 Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci USA 95:1091-1096
33. Saavedra HI, Knauf JA, Shirokawa JM, Wang J, Ouyang B, Elisei R, Stambrook PJ, Fagin JA 2000 The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 19:3948-3954
34. Mitsutake N, Knauf JA, Mitsutake S, Mesa Jr C, Zhang L, Fagin JA 2005 Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 65:2465-2473
35. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M 2005 The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115:1068-1081
36. Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M 2007 Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res 13:1341-1349
37. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428
38. Ain KB 2000 Management of undifferentiated thyroid cancer. Baillieres Best Pract Res Clin Endocrinol Metab 14:615-629
39. DeLellis RA 2006 Pathology and genetics of thyroid carcinoma. J Surg Oncol 94:662-669
40. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR 1999 Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5:810-816
41. Ichihara M, Murakumo Y, Takahashi M 2004 RET and neuroendocrine tumors. Cancer Lett 204:197-211
42. Plaza-Menacho I, Burzynski GM, de Groot JW, Eggen BJ, Hofstra RM 2006 Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet 22:627-636
43. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, Hirozane-Kishikawa T, Hill DE, Vidal M, Meyerson M, Grenier JK, Hinkle G, Root DE, Roberts TM, Lander ES, Polyak K, Hahn WC 2007 Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129:1065-1079
44. Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, Shih I 2005 Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 65:1994-2000
45. Perren A, Schmid S, Locher T, Saremaslani P, Bonvin C, Heitz PU, Komminoth P 2004 BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocr Relat Cancer 11:855-860
46. Sasaki H, Kawano O, Endo K, Suzuki E, Haneda H, Yukiue H, Kobayashi Y, Yano M, Fujii Y 2006 Uncommon V599E BRAF mutations in Japanese patients with lung cancer. J Surg Res 133:203-206